Fred R. Hirsch

51.7k total citations · 10 hit papers
383 papers, 21.7k citations indexed

About

Fred R. Hirsch is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Fred R. Hirsch has authored 383 papers receiving a total of 21.7k indexed citations (citations by other indexed papers that have themselves been cited), including 239 papers in Oncology, 234 papers in Pulmonary and Respiratory Medicine and 75 papers in Molecular Biology. Recurrent topics in Fred R. Hirsch's work include Lung Cancer Treatments and Mutations (196 papers), Lung Cancer Research Studies (124 papers) and Lung Cancer Diagnosis and Treatment (73 papers). Fred R. Hirsch is often cited by papers focused on Lung Cancer Treatments and Mutations (196 papers), Lung Cancer Research Studies (124 papers) and Lung Cancer Diagnosis and Treatment (73 papers). Fred R. Hirsch collaborates with scholars based in United States, Denmark and United Kingdom. Fred R. Hirsch's co-authors include Wilbur A. Franklin, Paul A. Bunn, Giorgio V. Scagliotti, Luis Paz‐Ares, James L. Mulshine, Walter J. Curran, Yi‐Long Wu, Regina Kwon, Marileila Varella‐Garcia and Heine H. Hansen and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Fred R. Hirsch

375 papers receiving 20.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lung cancer: current therapies and new targeted treatments

2016 2.5k citations Fred R. Hirsch et al. profile →
Social Limits to Growth

1976 1.1k citations Fred R. Hirsch et al. profile →
PD-L1 as a biomarker of response to immune-checkpoint inhibitors

2021 980 citations Fred R. Hirsch et al. profile →
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

2017 576 citations Hui Yu, Christopher J. Rivard et al. profile →
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

2006 570 citations Fred R. Hirsch, Marileila Varella‐Garcia et al. profile →
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary

2011 475 citations Charles A. Powell, Fred R. Hirsch et al. profile →
PD-L1 Expression in Lung Cancer

2016 336 citations Hui Yu, Fred R. Hirsch et al. profile →
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

2015 331 citations Fred R. Hirsch et al. profile →
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

2023 179 citations Zsolt Megyesfalvi, Paul A. Bunn et al. profile →
New promises and challenges in the treatment of advanced non-small-cell lung cancer

2024 116 citations Fred R. Hirsch et al. profile →

Peers

Countries citing papers authored by Fred R. Hirsch

Since Specialization

Citations

This map shows the geographic impact of Fred R. Hirsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred R. Hirsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred R. Hirsch more than expected).

Fields of papers citing papers by Fred R. Hirsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred R. Hirsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred R. Hirsch. The network helps show where Fred R. Hirsch may publish in the future.

Co-authorship network of co-authors of Fred R. Hirsch

This figure shows the co-authorship network connecting the top 25 collaborators of Fred R. Hirsch. A scholar is included among the top collaborators of Fred R. Hirsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred R. Hirsch. Fred R. Hirsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Calls to action on lung cancer management and research 2024 ·The Oncologist ·(unknown), Fred R. Hirsch, Paul A. Bunn, Peter Ujházy, (unknown), Christine D. Berg, David P. Carbone, Balázs Halmos, Harpreet Singh, Hossein Borghaei, Andrea Ferris, Corey J. Langer, Sanja Đačić, Tony Mok, Solange Peters, Bruce E. Johnson	1
2	Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment 2023 ·Cancers ·Ignace Vergote, Teresa Macarulla, Fred R. Hirsch, Carsten Hagemann, David S. Miller	12
3	Radiotherapy and Immunotherapy in Lung Cancer 2023 ·Biomedicines ·(unknown), Daniel R. Dickstein, (unknown), Eric J. Lehrer, Kenneth E. Rosenzweig, Fred R. Hirsch, Robert Samstein	10
4	Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403) 2022 ·Clinical Cancer Research ·Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara	31
5	Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States 2022 ·Cancer Medicine ·Rajwanth Veluswamy, Fred R. Hirsch, Emanuela Taioli, Juan P. Wisnivesky, (unknown), (unknown), Boxiong Tang, (unknown)	2
6	Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer 2021 ·Biology ·Dávid Dóra, Christopher J. Rivard, Hui Yu, (unknown), Viktória László, (unknown), Zsolt Megyesfalvi, Elek Dinya, (unknown), (unknown), Fred R. Hirsch, Balázs Döme, Zoltán Lohinai	27
7	Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis 2021 ·Lung Cancer ·Kohei Horiuchi, Takashi Sato, Toshiki Kuno, Hisato Takagi, Fred R. Hirsch, Charles A. Powell, Koichi Fukunaga	7
8	Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC) 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Fred R. Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh, Achim Rittmeyer, Cristóbal Belda-Iniesta, Dolores Isla, Thomas M. Cosgriff, Michelle Boyer, Mikio Ueda, Sem H. Phan, David R. Gandara	2
9	Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer 2013 ·Annals of Oncology ·Christoph Zielinski, Sylvia Knapp, Céline Mascaux, Fred R. Hirsch	67
10	Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention 2012 ·Cancer Prevention Research ·Céline Mascaux, William J. Feser, (unknown), Anna E. Barón, Christopher D. Coldren, Daniel T. Merrick, Timothy C. Kennedy, (unknown), (unknown), Wilbur A. Franklin, John D. Minna, Paul A. Bunn, York E. Miller, Robert L. Keith, Fred R. Hirsch	12
11	Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819 2012 ·Clinical Cancer Research ·Mary W. Redman, John J. Crowley, Roy S. Herbst, Fred R. Hirsch, David R. Gandara	38
12	Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers 2011 ·Cancer Prevention Research ·Robert L. Keith, Patrick J. Blatchford, John Kittelson, John D. Minna, Karen Kelly, Pierre P. Massion, Wilbur A. Franklin, Jenny Mao, David O. Wilson, Daniel T. Merrick, Fred R. Hirsch, Timothy C. Kennedy, Paul A. Bunn, Mark W. Geraci, York E. Miller	72
13	EGFR Protein Expression in Non–Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor—A Novel Antibody for Immunohistochemistry or AQUA Technology 2011 ·Clinical Cancer Research ·Céline Mascaux, Murry W. Wynes, Yasufumi Kato, Cindy Tran, Bernadette Reyna Asuncion, Jason M. Zhao, Mark Gustavson, Jim Ranger‐Moore, Fabien Gaire, Jun Matsubayashi, Toshitaka Nagao, Koichi Yoshida, (unknown), Norihiko Ikeda, Fred R. Hirsch	29
14	The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer 2010 ·Clinical Cancer Research ·Fred R. Hirsch, Murry W. Wynes, David R. Gandara, Paul A. Bunn	58
15	The Detection of Chromosomal Aneusomy by Fluorescence In situ Hybridization in Sputum Predicts Lung Cancer Incidence 2010 ·Cancer Prevention Research ·Marileila Varella‐Garcia, (unknown), Holly J. Wolf, William J. Feser, Chan Zeng, (unknown), Xiang Yin, Fred R. Hirsch, Timothy C. Kennedy, Robert L. Keith, Anna E. Barón, Steven A. Belinsky, York E. Miller, Tim Byers, Wilbur A. Franklin	38
16	Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications 2009 ·Clinical Cancer Research ·Charles M. Rudin, Érika Ávila-Tang, Curtis C. Harris, James G. Herman, Fred R. Hirsch, William Pao, Ann G. Schwartz, Kirsi Vähäkangas, Jonathan M. Samet	123
17	Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer 2008 ·Cancer Research ·Antonio Jimeno, Aik Choon Tan, Jordy Coffa, N.V. Rajeshkumar, Peter Kulesza, Belén Rubio‐Viqueira, Jenna Wheelhouse, Begoña Diosdado, Wells A. Messersmith, Christine A. Iacobuzio–Donahue, Anirban Maitra, Marileila Varella‐Garcia, Fred R. Hirsch, Gerrit A. Meijer, Manuel Hidalgo	72
18	[Mammography screening in the county of Copenhagen. Results of the first three screening rounds]. 2002 ·PubMed ·Ulla Brix Tange, Fred R. Hirsch, Maj‐Britt Jensen, Anne Helene Olsen, M Blichert-Toft, Fritz Rank, Ilse Vejborg, Henning T. Mouridsen, Elsebeth Lynge	6
19	[Mammographic screening in the county of Copenhagen. Clinical consequences of the first three screening rounds]. 2002 ·PubMed ·Ulla Brix Tange, Fred R. Hirsch, Maj‐Britt Jensen, Anne Helene Olsen, M Blichert-Toft, Fritz Rank, Ilse Vejborg, Henning T. Mouridsen, Elsebeth Lynge	1
20	Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. 2001 ·PubMed ·Paul A. Bunn, B. Helfrich, (unknown), Wilbur A. Franklin, Marileila Varella‐Garcia, Fred R. Hirsch, Anna E. Barón, Chan Zeng, Daniel C. Chan	131

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact